FORM 4
[X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Ugwumba Chidozie 2. Issuer Name and Ticker or Trading Symbol BiomX Inc. [ PHGE ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
_____ Officer (give title below)    __X__ Other (specify below)
Exit Form 4 - former 10% owner
(Last)          (First)          (Middle)
609 SW 8TH STREET, SUITE 365
3. Date of Earliest Transaction (MM/DD/YYYY)
9/16/2022
(Street)
BENTONVILLE, AR 72712
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  9/16/2022    S    3200  D $0.513  3346027 (1) I  By SymBiosis, LLC 
Common Stock  9/19/2022    S    13870  D $0.485  3332157 (1) I  By SymBiosis, LLC 
Common Stock  9/20/2022    S    10626  D $0.451  3321531 (1) I  By SymBiosis, LLC 
Common Stock  9/21/2022    S    5574  D $0.427  3315957 (1) I  By SymBiosis, LLC 
Common Stock  9/22/2022    S    17388  D $0.413  3298569 (1) I  By SymBiosis, LLC 
Common Stock  9/23/2022    S    5306  D $0.374  3293263 (1) I  By SymBiosis, LLC 
Common Stock  9/26/2022    S    17528  D $0.355  3275735 (1) I  By SymBiosis, LLC 
Common Stock  9/27/2022    S    4866  D $0.331  3270869 (1) I  By SymBiosis, LLC 
Common Stock  9/28/2022    S    15649  D $0.333  3255220 (1) I  By SymBiosis, LLC 
Common Stock  9/29/2022    S    3300  D $0.349  3251920 (1) I  By SymBiosis, LLC 
Common Stock  9/30/2022    S    8662  D $0.356  3243258 (1) I  By SymBiosis, LLC 
Common Stock  10/3/2022    S    15022  D $0.33  3228236 (1) I  By SymBiosis, LLC 
Common Stock  10/4/2022    S    19200  D $0.344  3209036 (1) I  By SymBiosis, LLC 
Common Stock  10/5/2022    S    46785  D $0.435  3162251 (1) I  By SymBiosis, LLC 
Common Stock  10/6/2022    S    25098  D $0.444  3137153 (1) I  By SymBiosis, LLC 
Common Stock  10/7/2022    S    24708  D $0.358  3112445 (1) I  By SymBiosis, LLC 
Common Stock  10/10/2022    S    10043  D $0.326  3102402 (1) I  By SymBiosis, LLC 
Common Stock  10/11/2022    S    5988  D $0.332  3096414 (1) I  By SymBiosis, LLC 
Common Stock  10/12/2022    S    9700  D $0.333  3086714 (1) I  By SymBiosis, LLC 
Common Stock  10/13/2022    S    11314  D $0.33  3075400 (1) I  By SymBiosis, LLC 
Common Stock  10/14/2022    S    3420  D $0.331  3071980 (1) I  By SymBiosis, LLC 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  The shares are directly held by SymBiosis, LLC.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Ugwumba Chidozie
609 SW 8TH STREET
SUITE 365
BENTONVILLE, AR 72712



Exit Form 4 - former 10% owner

Signatures
/s/ Chidozie Ugwumba 11/14/2022
**Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
BiomX (AMEX:PHGE)
Graphique Historique de l'Action
De Jan 2023 à Fév 2023 Plus de graphiques de la Bourse BiomX
BiomX (AMEX:PHGE)
Graphique Historique de l'Action
De Fév 2022 à Fév 2023 Plus de graphiques de la Bourse BiomX